Monthly Archives: December 2014

Page 3 of 3123

The Company has a novel silicate substituted calcium phosphate bone graft substitute.

The Company has a novel silicate substituted calcium phosphate bone graft substitute, Actifuse that the foundation of the company developed the guidance in applying the science of silicon bone graft technologies. The Company believes that ActifuseTM the first in a new class of synthetic bone replacement materials, the osteoconductive to combine accelerate speeding biostimulative properties bone formation and healing.

483 patients single plane MITLIF were evaluated: 411 were given rhBMP-2 and 93 ActifuseTM the incidence of new post-operative pain in the legs with rhBMP-2 is twice that seen with Actifuse also were postoperative VAS for upper. And lower leg pain at 6-12 weeks was significantly lower than in patients who are ActifuseTM. These very exciting results for ActifuseTM We are proud option for physicians option for physicians in the treatment of degenerative lumbar spine disease, said ApaTech CEO Simon Cartmell. Remains.e data further demonstrate ApaTech leadership in the science of silicon and the effects biostimulative ActifuseTM. . Continue reading

The age of relative at diagnosis is also a factor.

– The age of relative at diagnosis is also a factor. If the relative has been diagnosed before age 60, the increase in the risk will be higher. If it is diagnosed more than one first-degree relative with prostate cancer have their risk is about four times the average. To learn more visit here.

TITLE: Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage and insulin resistanceView article below:Bone Biology: Pathway to the genetic disease Faciogenital dysplasiaFaciogenital dysplasia is an inherited disorder characterized mainly by multiple skeletal defects. Mutations in the mutations in the gene FGD1, but how these mutations affect development of the skeleton remained an unanswered question. The work done in mice by a team of researchers from Laurie Glimcher, Harvard School of Public Health has now discovered a possible answer to this question and identifies a candidate therapeutic approach. Continue reading

Page 3 of 3123